Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) have been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price objective of $20.00 for the company and are forecasting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CytomX Therapeutics an industry rank of 93 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th.
Large investors have recently bought and sold shares of the company. American International Group Inc. increased its stake in CytomX Therapeutics by 165.7% in the second quarter. American International Group Inc. now owns 11,759 shares of the company’s stock worth $120,000 after buying an additional 7,333 shares in the last quarter. Nationwide Fund Advisors increased its stake in CytomX Therapeutics by 146.8% in the second quarter. Nationwide Fund Advisors now owns 12,925 shares of the company’s stock worth $132,000 after buying an additional 7,688 shares in the last quarter. Rhumbline Advisers acquired a new stake in CytomX Therapeutics during the second quarter worth $152,000. Metropolitan Life Insurance Co. NY acquired a new stake in CytomX Therapeutics during the second quarter worth $175,000. Finally, Swiss National Bank acquired a new stake in CytomX Therapeutics during the second quarter worth $230,000. Hedge funds and other institutional investors own 51.95% of the company’s stock.
Shares of CytomX Therapeutics (NASDAQ:CTMX) opened at 15.68 on Wednesday. The firm’s 50-day moving average is $13.40 and its 200 day moving average is $11.83. The stock’s market capitalization is $569.00 million. CytomX Therapeutics has a 1-year low of $9.01 and a 1-year high of $24.68.
CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. CytomX Therapeutics had a negative net margin of 579.42% and a negative return on equity of 91.59%. On average, analysts expect that CytomX Therapeutics will post ($1.59) EPS for the current fiscal year.
About CytomX Therapeutics
CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.